Image_2_Is Penicillin Plus Gentamicin Synergistic Against Sessile Group B Streptococcal Isolates? An in Vivo Study With an Experimental Model of Foreign-Body Infection.TIF by Corinne Ruppen (5216951)

“…In a rat tissue cage model, we evaluated the efficacy of adjunctive gentamicin (GEN) administered systemically (5 mg/kg body weight) every 24 h, or locally (12.5 mg/L tissue cage concentration) every 24 or 72 h, in combination with penicillin (PEN) administered systemically (250,000 IU/kg body weight three times per day). …”

Data_Sheet_1_An Arabidopsis Cytokinin-Modifying Glycosyltransferase UGT76C2 Improves Drought and Salt Tolerance in Rice.docx by Yanjie Li (1463440)

“…<p>Drought and salt stresses are common environmental threats that negatively affect rice development and yield. Here we report that the overexpression of AtUGT76C2, a cytokinin glycosyltransferase, in rice modulates cytokinin homeostasis and confers the plants an eminent property in drought and salt tolerance. …”

DataSheet1_High-Temperature and High-Pressure Phase Transition of Natural Barite Investigated by Raman Spectroscopy and Electrical Conductivity.docx by Meiling Hong (1676641)

“…<p>We investigated the structural, vibrational, and electrical transport properties for natural barite under the conditions of 298–873 K and 1.5–35.0 GPa using a diamond anvil cell by virtue of Raman spectroscopy and electrical conductivity measurements. …”

Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid‑1 Receptor Antagonists for Metabolic Syndrome Disorders by Szabolcs Dvorácskó (14767447)

“…We have designed orally bioavailable, non-brain-penetrant antagonists of the cannabinoid-1 receptor (CB₁R) with a built-in biguanide sensor to mimic 5′-adenosine monophosphate kinase (AMPK) activation for treating obesity-associated co-morbidities. …”

Supplementary Material for: The Effects of Chronic Subcutaneous Administration of an Investigational Kisspeptin Analog, TAK-683, on Gonadotropin-Releasing Hormone Pulse Generator A... by Yamamura T. (4150090)

“…We examined the effects of chronic administration of TAK-683, an investigational kisspeptin analog, on LH secretion, GnRH immunostaining, pituitary responses to exogenous GnRH, and GnRH pulse generator activity, reflected by a characteristic increase in multiple-unit activity (MUA volley). …”

Image_4_Is Penicillin Plus Gentamicin Synergistic Against Sessile Group B Streptococcal Isolates? An in Vivo Study With an Experimental Model of Foreign-Body Infection.TIF by Corinne Ruppen (5216951)

“…In a rat tissue cage model, we evaluated the efficacy of adjunctive gentamicin (GEN) administered systemically (5 mg/kg body weight) every 24 h, or locally (12.5 mg/L tissue cage concentration) every 24 or 72 h, in combination with penicillin (PEN) administered systemically (250,000 IU/kg body weight three times per day). …”

Data_Sheet_1_Is Penicillin Plus Gentamicin Synergistic Against Sessile Group B Streptococcal Isolates? An in Vivo Study With an Experimental Model of Foreign-Body Infection.DOC by Corinne Ruppen (5216951)

“…In a rat tissue cage model, we evaluated the efficacy of adjunctive gentamicin (GEN) administered systemically (5 mg/kg body weight) every 24 h, or locally (12.5 mg/L tissue cage concentration) every 24 or 72 h, in combination with penicillin (PEN) administered systemically (250,000 IU/kg body weight three times per day). …”

The Mitochondrial Chaperone Protein TRAP1 Mitigates α-Synuclein Toxicity by Erin K. Butler (185540)

“…We used a whole-genome screen in the fruit fly <em>Drosophila melanogaster</em> to search for novel genetic modifiers of human [A53T]α-Synuclein–induced neurotoxicity. …”

Data_Sheet_1_Longitudinal study of the interplay between the skin barrier and facial microbiome over 1 year.pdf by Jung Yeon Seo (6000647)

“…Notably, Cutibacterium and skin barrier parameter, TEWL, exhibited a co-decreasing pattern from winter to summer and showed a significant association between Cutibacterium and TEWL. …”

Genome-wide changes in expression upon perturbation of the TBP regulatory network by Kathryn L Huisinga (30385)

“…</p><p>Published online 2 Apr 2007</p><p>PMCID:PMC1896006.</p><p></p> We grouped 2,903 ORFs (rows) that changed expression by at least 1.5-fold in at least one of the 63 conditions (columns) examined into 10 clusters using the K-means algorithm [63]. …”

Antibody production in immunized and challenged chickens. by Marta Matulova (126441)

“…As competitive ELISA was used, the increase in anti-flagellin antibody is characterized by a decrease in absorbance. Diamonds, SPI1-<i>lon</i>::Cm vaccinated chickens; squares, SPI1- <i>lon</i>::Cm-<i>fliC</i> vaccinated chickens; triangles, SPI1- <i>lon</i>::Cm-<i>fliC</i>-<i>rcsB</i>::Kan vaccinated chickens; circles, non-vaccinated chickens. * - significantly different from the non-infected controls sacrificed on day 42 by Kruskal-Wallis and post hoc Dunn’s test at P<0.05 (panels A and B) or day 46 (panels C and D).…”

Video2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Video2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Image2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Video1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Image4_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Video3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Image3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”

Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD₉₀ prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”